Fortress Biotech Stock Performance
| FBIO Stock | USD 1.61 0.04 2.55% |
The firm shows a Beta (market volatility) of 1.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fortress Biotech will likely underperform. At this point, Fortress Biotech has a negative expected return of -0.35%. Please make sure to confirm Fortress Biotech's skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Fortress Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fortress Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:15 | Last Split Date 2023-10-10 |
1 | Disposition of 8000 shares by Rowinsky Eric K of Fortress Biotech at 4.31 subject to Rule 16b-3 | 09/06/2024 |
2 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 18, 2024 in New Fortress Lawsuit - NFE | 10/28/2024 |
3 | New Fortress Energy Inc. Sued for Securities Law Violations Investors Should Contact Levi Korsinsky Before November 18, 2024 to Discuss Your Rights NFE | 11/04/2024 |
4 | Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates | 11/12/2024 |
5 | NFE LAWSUIT ALERT Levi Korsinsky Notifies New Fortress Energy Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | 11/13/2024 |
6 | Shareholders of New Fortress Energy Inc. Should Contact Levi Korsinsky Before November 18, 2024 to Discuss Your Rights - NFE | 11/15/2024 |
7 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 18, 2024 in New Fortress Energy Inc. Lawsuit - NFE | 11/18/2024 |
8 | New Fortress Energy hires advisors to explore possible asset sales - Bloomberg | 11/19/2024 |
9 | Fortress Acquires Texas Hydraulics, Leading Hydraulic Solutions Company | 11/21/2024 |
| Begin Period Cash Flow | 181 M |
Fortress |
Fortress Biotech Relative Risk vs. Return Landscape
If you would invest 215.00 in Fortress Biotech on August 24, 2024 and sell it today you would lose (54.00) from holding Fortress Biotech or give up 25.12% of portfolio value over 90 days. Fortress Biotech is currently does not generate positive expected returns and assumes 4.3849% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Fortress, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fortress Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fortress Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fortress Biotech, and traders can use it to determine the average amount a Fortress Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0805
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FBIO |
Estimated Market Risk
| 4.38 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fortress Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fortress Biotech by adding Fortress Biotech to a well-diversified portfolio.
Fortress Biotech Fundamentals Growth
Fortress Stock prices reflect investors' perceptions of the future prospects and financial health of Fortress Biotech, and Fortress Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fortress Stock performance.
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (1.69) % | ||||
| Current Valuation | 56.02 M | ||||
| Shares Outstanding | 27.56 M | ||||
| Price To Earning | (2.92) X | ||||
| Price To Book | 2.05 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 84.51 M | ||||
| Gross Profit | (85.66 M) | ||||
| EBITDA | (133.64 M) | ||||
| Net Income | (60.64 M) | ||||
| Cash And Equivalents | 208.35 M | ||||
| Cash Per Share | 1.92 X | ||||
| Total Debt | 88.59 M | ||||
| Debt To Equity | 1.24 % | ||||
| Current Ratio | 2.43 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (128.22 M) | ||||
| Earnings Per Share | (27.73) X | ||||
| Market Capitalization | 46.86 M | ||||
| Total Asset | 167.53 M | ||||
| Retained Earnings | (694.87 M) | ||||
| Working Capital | 32.11 M | ||||
| Current Asset | 99.94 M | ||||
| Current Liabilities | 10.58 M | ||||
About Fortress Biotech Performance
By examining Fortress Biotech's fundamental ratios, stakeholders can obtain critical insights into Fortress Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Fortress Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 139.73 | 146.72 | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (1.72) | (1.81) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (2.69) | (2.82) |
Things to note about Fortress Biotech performance evaluation
Checking the ongoing alerts about Fortress Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fortress Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fortress Biotech generated a negative expected return over the last 90 days | |
| Fortress Biotech may become a speculative penny stock | |
| Fortress Biotech has high historical volatility and very poor performance | |
| Fortress Biotech has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 84.51 M. Net Loss for the year was (60.64 M) with loss before overhead, payroll, taxes, and interest of (85.66 M). | |
| Fortress Biotech currently holds about 208.35 M in cash with (128.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fortress Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Fortress Acquires Texas Hydraulics, Leading Hydraulic Solutions Company |
- Analyzing Fortress Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fortress Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Fortress Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fortress Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fortress Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fortress Biotech's stock. These opinions can provide insight into Fortress Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.73) | Revenue Per Share 6.15 | Quarterly Revenue Growth (0.14) | Return On Assets (0.36) | Return On Equity (17.40) |
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.